AI is being explored at every stage of the pharmaceutical product lifecycle, from drug discovery to post-market surveillance. In discovery, AI can automate the analysis of vast, unstructured datasets (e.g., patents and clinical trial data) enabling faster, more comprehensive, insights. AI models can also assess chemical compounds for stability, tolerability, and efficacy, streamlining lead compound selection.

In clinical development, AI has the potential to transform patient recruitment by identifying optimal patient profiles and generating bespoke recruitment materials. The use of "virtual human twins" – computational models that simulate human physiology and disease – can help to predict patient responses and optimize dosing. The European Commission's investment of over €100 million in the European Virtual Human Twin program highlights the prioritization of this early-stage use case.

AI's impact is also emerging in supply chain management, where it can enhance quality assurance by detecting manufacturing deviations and proposing real-time solutions. Predictive maintenance algorithms can anticipate equipment needs, reducing downtime and improving production efficiency.

Commercialization is beginning to benefit, as AI can be used to analyze historical launch data, competitor activity, and pricing trends to optimize launch strategies. In pricing and reimbursement, AI can simulate payor responses and negotiation dynamics. In pharmacovigilance, AI can enable real-time monitoring of adverse event data and prioritize reports for human review.

As AI becomes integral to pharmaceutical operations, robust regulation is essential. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) is taking a proactive approach, positioning the UK as a global leader in AI regulation. The MHRA is currently gathering evidence to inform the National Commission into the Regulation of AI in Healthcare, demonstrating a commitment to stakeholder engagement and forward-thinking policy.

Innovative initiatives such as the "AI Airlock" – a regulatory sandbox for real-world testing of AI in healthcare – are being piloted, alongside the launch of the UK National Commission on the Regulation of AI in Healthcare.

For AI systems supporting manufacturing, the MHRA has informally confirmed that those used solely for manufacturing purposes (such as designing immunotherapies) will be regulated under Good Manufacturing Practice (GMP), not as medical devices under the Medical Device Regulations 2002 (MDR). Only AI systems with a direct medical purpose will fall under MDR. This distinction is welcomed by industry, as GMP requirements are generally more familiar and less burdensome than medical device regulations.

These progressive initiatives highlight the UK's ambition to lead in safe, innovative AI adoption across the pharmaceutical sector.